Case Report: When cystic fibrosis, elexacaftor/tezacaftor/ivacaftor therapy, and alpha1 antitrypsin deficiency get together

• Päätekijät: Rachel Kinuani (Tekijä), Jessica Ezri (Tekijä), Yann Kernen (Tekijä), Isabelle Rochat (Tekijä), Sylvain Blanchon (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Frontiers Media S.A., 2024-04-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

In the last 10 years, the care of patients with cystic fibrosis (CF) has been revolutionized with the introduction of cystic fibrosis transmembrane conductance regulator (CFTR) modulator drugs, with a major impact on symptoms and life expectancy, especially considering the newest and highly effectiv...